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Abstract 
The 18 kDa Translocator Protein (TSPO) localizes in the outer mitochondrial membrane of the cells 
and is readily up-regulated under various pathological conditions such as cancer, inflammation, 
mechanical lesions, and neurological diseases. Capable to bind with high affinity synthetic and 
endogenous ligands, its core biochemical function resides in the translocation of cholesterol into the 
mitochondria influencing the subsequent steps of (neuro-) steroid synthesis and systemic endocrine 
regulation.  
Over the years however TSPO has also been linked to core cellular processes such as apoptosis and 
autophagy. It interacts and forms complexes with other mitochondrial proteins such as the voltage-
dependent anion channel (VDAC) via which signaling and regulatory transduction of these core 
cellular events may be influenced. Despite nearly 40 years of study, the precise functional role of 
TSPO beyond cholesterol trafficking remains elusive even though the recent breakthroughs on its 
high-resolution crystal structure and contribution to quality control signaling of mitochondria.  
All this along with a captivating pharmacological profile naturally provides novel opportunities for 
investigating and understanding the significance of this highly conserved protein and the envisaged 
therapeutics development as here presented and discussed. 
 
Summary statement 
An alternative binding site for the benzodiazepines was discovered in the periphery of the central 
nervous system at the end of the seventies. Since then, the Peripheral Benzodiazepines Receptor 
(PBR), as it was initially named before the current nomenclature of Translocator Protein (TSPO), has 
exponentially gained interest from various disciplines of experimental and applied biomedicine. 
Inspired by the series of discoveries recorded in the past twelve months we here aim to review the 
most compelling aspects of TSPO science in order to inform on the biochemical and molecular 
pharmacology, homeostatic relevance and therapeutic potential of this mitochondrial stress-response 
pathway. 
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Pharmacology 
 
Abbreviations: Translocator Protein (TSPO); Peripheral Benzodiazepine Receptor (PBR); Voltage-
Dependent Anion Channel (VDAC); 
Introduction 
The cross-disciplinary nature of TSPO has been recently remarked by prominent discoveries, which 
have pointed out this as an underlying regulatory pathway in cell homeostasis and signaling to fine-
tune mitochondrial function and its quality control to acute and chronic stress conditions. This has 
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indeed unveiled a fundamental relevance in the molecular and biochemical physiopathology of 
mitochondria and their interplay with the intracellular environment. 
TSPO was discovered in the 1977(1) and initially named as the peripheral benzodiazepine receptor 
(PBR) for the ability to bind benzodiazepine drugs outside of the central nervous system. It is an 
abundant, evolutionary conserved, protein found in every organs but with particularly high constitutive 
expression in steroidogenic tissue, including adrenal glands, gonads, placenta and activated brain 
microglia (2-4). 
The pattern of TSPO expression and the early discovery that TSPO was an high-affinity binding 
protein of cholesterol resident in the outer mitochondrial membrane, established an exciting link 
between cholesterol transport and biosynthesis of steroids, including the neuronal kind of these (2, 5, 
6). A large body of evidence has gradually defined TSPO as an essential component of cholesterol 
transport across the mitochondrial membrane and a rate-limiting step of steroid hormone production 
(7-10). This feature, in addition to the putative roles in protein import, porphyrins binding and transport, 
resulted in a new nomenclature as Translator Protein. Remarkably, this was introduced almost 30 
years after its discovery and adopted to better describe TSPO function as cholesterol-translocator 
protein replacing the original name (11, 12).  
TSPO is widely expressed throughout the body yet its density appears tissue-dependent. 
Steroidogenic tissues possess the majority of the protein whereas renal and myocardial tissues have 
reduced levels, and lower still, the brain and liver (13-15). Notably, distribution is not homogenous 
within a given organ. For instance, in the adrenal glands, the medulla is almost lacking in TSPO, while 
far greater levels of the protein are expressed in the cortex (16). It is localized to the outer 
mitochondrial membrane (2, 17, 18), and for this we call it a mitochondrial protein however it has been 
reported in the nucleus (19) and on the plasma membrane (20). Hitherto neither of these two 
alternative localizations has been properly validated.  
TSPO expression rises readily in various cell types following exposure to pro-pathological stressors 
or physicochemical insults (10, 21, 22). Such a dynamic increase of expression is particularly evident 
in microglia cells of the brain (23), which has led TSPO to be exploited for diagnostic purposes as a 
biomarker of active disease or disease-related tissue remodeling through the generation of TSPO 
radioligands (12, 21).  
The recurring association with cell and tissue pathology likewise its known druggability have made 
TSPO an attractive therapeutic target. Various are indeed the chemical entities with affinity for TSPO 
that have been reported with some of which entering clinical trials as either diagnostics or therapeutics 
(12). 
Animal models of disease that were reported to benefit from treatments with TSPO ligands include 
those for Alzheimer’s Disease (AD), Multiple Sclerosis (MS), anxiety disorders, neuropathic pain, 
peripheral nerve injury, diabetes, rheumatoid arthritis, cancer and cardiac ischemia (21, 24-30). 
Among the therapeutic interventions exploiting TSPO the most promising one, hitherto, is based on 
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the prediction that neurosteroids could be beneficial in the treatment of inflammation and selective 
TSPO ligands would consequently hold a therapeutic potential by promoting the function of TSPO in 
steroidogenesis (21, 24, 31).   
A role for TSPO in the formation of the mitochondrial membrane permeability transition pore (MPTP) 
has been for long proposed, providing a rationale for the evidences linking TSPO with apoptosis, Ca2+ 
signaling and redox stress homeostasis. However, recent studies on gene-edited mice (knocked out 
for TSPO) have ruled this out and showed that MPTP is formed regardless of the presence of TSPO 
(32-36). Nevertheless, a regulatory role for TSPO and that of its drug ligands cannot be excluded. 
Several are the endogenous ligands for TSPO such as diazepam binding inhibitors (DBIs), porphyrins 
and cholesterol. There is substantial literature to date that describes cholesterol binding but much 
less about the physiological relevance of DBIs and porphyrins. DBIs exhibit micromolar affinity with 
both TSPO and the central benzodiazepine receptor, and are widely distributed in glial cells of the 
CNS and in steroidogenic peripheral tissues (37). They may be cleaved into other biologically active 
fragments and are shown to stimulate steroidogenesis via interactions with TSPO (38). Porphyrins, 
tetrapyrrolic pigments important in heme biosynthesis pathways, may be scavenged by TSPO (39, 
40). A number of interacting proteins (e.g. ACDB3, ACBD1, PRAX1, VDAC, 14-3-3, phospholipase 
A2) have been identified, which are involved in steroidogenesis and other TSPO-related functions 
including apoptosis and autophagy. Notably, the molecular link between TSPO and the Voltage 
Dependent Anion Channel (VDAC), a core element of the mitochondrial outer membrane, is restated 
by most of the recent literature, which highlights novel functional significance for this protein (41).   
In this review we will outline the current knowledge and the implications of the most recent findings in 
the understanding of TSPO as core molecular determinant of mitochondrial biochemistry and 
pharmacology.  
 
TSPO and a bi-directional transcriptional signaling network  
The Tspo gene is composed of four exons, with a large intron that separates the first two. Multiple 
transcription start sites have been identified in the Tspo promoter in different species (42). The 
promoter lacks a TATA box or CCAAT elements but contains proximal GC-rich motifs and five tandem 
binding sites for specificity protein 1/ specificity protein 3 (Sp1/Sp3) factors. The promoter region also 
harbors putative binding sites that are conserved between mouse and human TSPO for a number of 
additional transcription factors including activator protein 1 (AP1), v-ets erythroblastosis virus E26 
oncogene homolog (Ets) transcription factors, Myc and STAT members (42-46).It is likely that tissue-
specific regulatory elements exist as in steroidogenic MA-10 and Y1 cells 585 base pairs of the 
promoter was required to maintain full activity compared to an extended 805 bp region in non-
steroidogenic NIH-3T3 cells (42).  
Tspo is predominantly under the control of a PKC -dependent signal transduction pathway, which is 
constitutively active in steroidogenic and inducible in non-steroidogenic cells (46, 47). PKC  activates 
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the Raf-MEK-ERK MAPK pathway and triggers Tspo transcription through cooperation with c-Jun, 
Ets, AP1 and STAT3 transcription factors(46-48). Basal Tspo transcription requires Ets and Sp1/Sp3 
transcription factors (48), which are located in promoter regions 805-515 and 123-1 (47). Evidence 
has demonstrated that TSPO is directly related to changes in ROS generation and there are multiple 
ROS-sensitive elements that drive the expression of the Tspo gene, such as AP1, ERK1/2 and PKC
(46, 48). For example, increased ROS production in astrocytes results in nuclear accumulation of 
the Sp1 transcription factor, which increases TSPO mRNA (49). Upregulation of TSPO has also been 
observed after treatment with other ROS-producing compounds including TNFα (50, 51), phorbol-12-
myristate 13-acetate (PMA) (46, 52) and the mitogen-activated protein kinase kinase (MEK) inhibitor, 
2-(2’-amino-3’-methoxyphenyl)-oxanophthalen-4-one (PD98059) (48). 
We have shown that overexpression of TSPO is associated with increased ROS production, which 
we have reported as a causative factor in TSPO-mediated mitophagy inhibition(41). The idea that 
overexpression of TSPO creates an oxidative cellular environment is very important as the expression 
of the Tspo is driven by downstream effectors of ROS (48). Under oxidative conditions, an increase 
in TSPO levels may be physiologically important to provide mitochondrial and cellular protection 
against initial ROS damage; should this be sustained, a positive feedback cycle in which the gene is 
re-expressed and mitophagy continuously impaired may manifest by leading to cumulative 
mitochondrial damage, which would impact cell and tissue health over time (53). 
There are anyway reports showing, on the contrary, that sustained oxidative stress decreases TSPO 
expression contributing cell death (22, 48) although the transcriptional or protein degradation 
pathways in such conditions are ill-defined. 
Numerous hormones including estradiol and aldosterone also regulate TSPO (48, 54, 55); the 
presence of hormones appears to be necessary for maintaining constitutive TSPO expression, since 
decrease in TSPO is observed in steroidogenic tissues following surgical removal of the pituitary 
gland (6) and the adrenal gland (54). Several studies have described that exposure to steroid 
hormones modifies TSPO levels, determined through TSPO binding studies (56-58). mRNA and 
protein levels do not always correlate, however, and the protein is reported to undergo conformational 
changes that result in increased ligand binding (55, 59). Hormones do cause a change in TSPO 
binding affinity to typical ligands and induce structural alterations including post-translation 
modifications such as cyclic adenosine monophosphate (cAMP, cyclic AMP, or 3'-5'-cyclic adenosine 
monophosphate)- dependent PKA-mediated phosphorylation (48, 60).  
It is well established that hormones activate the cAMP pathway, being an important element in 
steroidogenesis contributing to lipid synthesis, cholesterol trafficking and protein phosphorylation. 
cAMP is a second messenger important in many biological processes including growth and 
differentiation, and is used for intracellular signal transduction in many different organisms.  
Activation of the cAMP pathway leads to a redistribution of Acyl-coenzyme A binding domain 
containing 3 (ACBD3) from the Golgi to mitochondria, where it interacts with TSPO and recruits PKA 
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(61, 62). This has relevance in the activation of steroidogenesis and has been described in estradiol-
induced neuroprogesterone synthesis in the hypothalamic astrocytes (63).   
Prolonged exposure to hormones including estradiol can lead to a decrease in TSPO levels, signifying 
a feedback mechanism (48, 55). A negative feedback loop has been described to regulate Tspo 
transcription following the identification of microtranscriptional regulation by cAMP dependent natural 
antisense transcripts (NAT). Antisense transcription was initially considered as transcriptional noise, 
however, it is increasingly becoming recognized as an important regulator of gene expression and 
may form self-regulatory circuits that allow genes to regulate their own expression [for review see 
(64)]. At the Tspo locus a short interspersed element (SINE) of the B2 family was identified that was 
able to drive the expression of long transcripts. Its extension overlapped exon 3 of the Tspo gene and 
formed a NAT specific for Tspo that was dependent on cAMP (65).  
Alternatively, peroxisome proliferator-activated receptor alpha (PPAR) (66) has been linked to 
decreases in TSPO expression (48, 67-69). PPAR interferes with ROS-activated NFκB, STATs and 
AP-1 transcription signaling pathways (70), factors with binding sites in the Tspo promoter (47, 48). It 
has been also suggested that PPAR reduces the binding of AP-1 to its PKC-associated site on the 
Tspo promoter resulting in a decrease in TSPO mRNA (48) while previous studies have shown a 
positive correlation between PPARs and increased TSPO expression (52). Interestingly, activation of 
PPAR may also occur via a cAMP-PKA dependent mechanism creating a further compatible 
regulatory mechanism as activation of PPAR does bear anti-inflammatory effect (71-73), which may 
be logically linked to a decrease in TSPO expression (Figure 1).  
What emerges from the existing literature is that TSPO represents an important element in facilitating 
cellular adaptation to various pathological and pro-pathological stimuli by integrating hormone and 
REDOX sensitive pathways. 
Detailed identification of the transcriptional regulatory pathways and feedback loops could prove 
fundamental to our understanding of this protein’s function and responsiveness to stress conditions. 
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TSPO and its phylogenetic structure 
TSPO has tryptophan-rich regions that are highly conserved between prokaryotes and eukaryotes 
(Figure 2). The structure of TSPO was first predicted based on its secondary structure and modelled 
using molecular dynamics simulation to give a two-dimensional membrane topological model 
comprising an intramitochondrial short amino-terminal region and five amphipathic α-helices linked 
by hydrophilic loops leading to an extramitochondrial carboxyl-terminal tail (74).  
An early 3D structure of TSPO, built upon the 7 transmembrane rhodopsin structure, which was 
almost the only membrane protein structure available at the time, was modelled as only long enough 
to span one phospholipid layer rather than crossing the entire bilayer membrane (74). Later TSPO 
topological classification in the mitochondrial membranes of yeast supported a five-transmembrane 
structure but with extended α-helices that are in fact able to traverse the entire membrane bilayer 
(75). However, CD spectrum results from mouse TSPO (MmTSPO) demonstrated the presence of a 
mainly helical secondary structure while NMR data confirmed the presence of at least five helical 
transmembrane segments (76).  
Bacterial homologues have also been used to provide detailed insights into the structure of TSPO: 
TSPO from Rhodobacter sphaeroides (RsTSPO), one of the closest ancestors of mitochondria, not 
only has a primary structure similar to that of human TSPO but is also reported to have functional 
similarities (77). Cryo-EM and image analysis studies of RsTSPO revealed a dimeric, five 
transmembrane domain architecture for TSPO at 10 Å resolution (78).  
This structural information indicated monomeric TSPO could function as a channel and could 
therefore translocate cholesterol across the outer mitochondrial membrane, in line with its well-
defined role in steroidogenesis (21, 79). Recently, a high-resolution structure of mammalian TSPO 
reconstituted in detergent micelles in complex with the ligand PK 11195 has been obtained, further 
supporting a five transmembrane alpha helical conformation (80).  
Another powerful study has described crystal structures for Bacillus cereus TSPO (BcTSPO) at 1.7 Ǻ 
resolution in complex with PK 11195. These authors demonstrated oxidative catalytic activity between 
TSPO and PpIX (protoporphyrin IX), a reaction also observed in TSPO from Xenopus tropicalis and 
Homo sapiens that leads to PpIX degradation. This has been attributed to ROS-mediated generation 
of tryptophan radicals at residues W53 (hs numbering; transmembrane domain 2) and W143 (hs 
numbering; transmembrane domain 5), which are both shown to participate in the stabilization and 
cleavage of PpIX. Two other conserved tryptophan residues are located in Loop 1 (W32 and W40; hs 
numbering) and in the cholesterol recognition amino acid consensus (CRAC) cytoplasmic domain 
located at the C-terminus (W155; hs numbering), which are considered to be important in other TSPO-
ligand and –protein interfaces (77, 81-83). The identification of potential catalytic regions in TSPO is 
particularly interesting and it would be worth understanding how such biochemical activity influences 
TSPO molecular interactions and downstream processes under conditions of REDOX stress since 
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different experimental conditions are already known to affect Kd values for PpIX binding; e.g. 0.3 μM 
(81) versus 8.6 μM (78). 
Quite notably, TSPO has been characterized in monomeric, dimeric and multimeric states although 
the functional significance of its polymerization requires further clarification. Analysis of RsTSPO 
revealed a dimer (78, 81) while studies on MmTSPO portray a monomeric protein in complex with PK 
11195 (80) although there is a possibility of oligomeric states (84). BcTSPO on the other hand has 
been extracted as monomeric, dimeric and as higher oligomeric species with a dimeric model in 
complex with PK 11195 (40).  Interestingly, cellular REDOX status has been previously linked with 
TSPO oligomeric status s in response to ROS increases TSPO preferentially forms covalent polymers 
(85).  
TSPO can function both as a monomer and polymer. In its monomeric form TSPO binds PK 11195 
and cholesterol with nanomolar affinity (79) although the translocation of cholesterol is preferentially 
mediated through polymeric forms or in complex with other protein binding partners (86).  
A TSPO genetic polymorphism in humans Ala(147)  Thr(147) is associated with psychiatric 
disorders (87-89) and reduced pregnenolone production (90).  
The polymorphism resides one helical turn before the CRAC cholesterol binding motif, and a reduction 
in cholesterol binding has been identified with a four- to fivefold lower affinity than wild-type (91, 92). 
Complications in the application of certain TSPO PET ligands, including [11C]-PBR28, [18F]-PBR111 
and [(18)F]-FEPPA for imaging brain inflammation have been linked to this polymorphism (88, 93-
96). However, structural analyses have shown that A147T TSPO is able to retain the same structural 
profile as the wild-type protein, and binds the first generation TSPO ligand, PK 11195, with 
comparable affinity (97). Contradictory to this study, which used mTSPO (97), RsTSPO A139T 
exhibited a lower binding affinity to PK 11195 as well as PpIX (92) and this is supported by crystal 
structures of the A139T mutant at 1.8 and 2.4 Ǻ resolution in RsTSPO, which show conformational 
changes that alter the structural environment in both the CRAC domain and possible ligand binding 
domains. These conflicting reports however can be ascribed to the structural differences between 
mammalian and bacterial species. Nevertheless, they still raise the question as to how functional 
activity data obtained in bacterial systems can be applied to mammalian TSPO and therefore if this 
has been preserved intact in the phylogenesis. Additional studies conducted in mammalian TSPO 
systems will therefore be of essence particularly with regards to the apparent catalytic activity 
exhibited by TSPO in the degradation of PpIX as already pointed out (40).  
Anyhow the tremendous effort by colleagues who endeavored, in series, to generate the actual 
structure of the protein is of invaluable importance not only to inform TSPO biochemistry but also to 
pave novel avenues of research to dissect and exploit the nature of TSPO-ligands binding as well as 
the design of novel chemicals. 
 
Tspo-/- knockout mice: new insights of an old function  
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The most studied role assigned to TSPO is in the transport of cholesterol into mitochondria for 
hormone biosynthesis. Hormone-induced steroidogenesis in all tissues begins with the conversion of 
the precursor cholesterol to pregnenolone, a reaction catalysed by the enzyme P450 cholesterol side 
chain cleavage enzyme (CYP11A1), located in the IMM, facing the matrix [reviewed in (98)]. The rate-
limiting step is the transport of cholesterol from the cellular stores across the mitochondrial 
membranes. In order for this step to be achieved, cholesterol must accumulate at the outer 
mitochondrial membrane (OMM) and then be transferred to the IMM.  
The steroidogenic acute regulatory protein (StAR) is a hormone induced mitochondria-targeted 
protein that has been shown to initiate cholesterol transfer into mitochondria (99-101). It binds 
cholesterol (102) and is active at the OMM where it is proposed to interact with TSPO to form a 
complex that facilitates mitochondrial cholesterol import (62, 101, 103, 104). Other components of the 
complex include ACBD3 (Acyl-coenzyme A binding domain containing 3) and the regulatory subunit 
R1α of PKA (62, 83, 105). TSPO can bind cholesterol through its CRAC domain (106), and 
mutagenesis in this region interferes with cholesterol binding and transfer of cholesterol into the IMM, 
preventing steroidogenesis (107). TSPO gene silencing blocks cholesterol transport into the 
mitochondria, also reducing steroid production, while reintroduction of TSPO is able to restore 
steroidogenic capacity (83). Parallel studies conducted in a bacterial system expressing MmTSPO 
demonstrated time- and temperature-dependent uptake of radiolabeled cholesterol. A number of non-
steroidal ligands that interact with the CRAC motif were recently identified through molecular modeling 
and in silico screening of chemical libraries and were shown to potently inhibit steroidogenesis (108). 
Taken together there is a large body of evidence supporting a function for TSPO in cholesterol 
transport; although it has also been suggested that it stores cholesterol until later requirement since 
cholesterol loaded membranes release cholesterol in response to PK 11195 (79, 109). 
Recently, however, a number of studies from independent groups have reported that TSPO global 
knock out mice are viable and that loss of the protein has no effect on basal steroid hormone 
biosynthesis (32, 35, 110, 111). These studies not only question the role TSPO holds in 
steroidogenesis but contrast early attempts to generate Tspo-/- knockout mice, which resulted in 
embryonic lethality (5). However, the viability of mice has been shown to vary depending on 
methodology: Nr5a1-driven conditional knock-outs were born at a normal Mendelian ratio while 
Amhr2-Cre driven conditional knock-outs were born at a ratio of 4.4% (111). Global Tspo knockout 
phenotypes can range from lethal, when whole gene deletion is performed, to no phenotype, as in 
the case of cre-loxP technique, thus presenting the possibility that methodological differences may 
be the cause of such discrepancy (112). Phenotypic characterization carried out on currently available 
global and conditional knock-out strains is summarized in Table 1. However, it is important to consider 
that compensatory mechanisms may play an important part in ensuring ongoing steroidogenesis in a 
TSPO null setting, and these may be different in the various strains, which may be attributed to 
methodology as highlighted already. In both global and conditional Tspo knock-out studies, several 
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genes involved in steroidogenic processes were found to be upregulated including Cyp21a2 (110), 
Abca2 (110), and Scarb1 (111) in the adrenal glands and Lhcgr (111) in the testes (Table 2). The 
study by Fan et al describes how tissue-specific deletion of Tspo in gonadal tissues had little effect 
on gonadal steroidogenesis although ACTH stimulation of corticosterone production in Tspo depleted 
adrenals was severely impaired in both male and female animals (111). Interestingly, in Tspo-/- mice, 
there is an accumulation of lipid droplets in the adrenal glands, implying decreased lipid metabolism, 
while instead lipid stores were depleted in testes and ovaries, implying excessive substrate 
consumption (111). These observations provide strong evidence that there is an important role for 
TSPO in hormone-mediated steroidogenesis and lipid and cholesterol metabolism.  
TSPO is also attributed to immune regulation, with elevated expression observed in microglia and 
macrophages. Recently it was highlighted that TSPO is involved in cholesterol trafficking in 
macrophages, since its overexpression leads to increased transcription of proteins involved in 
cholesterol efflux, ACBA1 (ATP-binding cassette A1), PPARα (peroxisome-proliferator-activated 
receptor α) and LXRα (liver X receptor α), and corresponds with increased efflux of cholesterol to 
acceptors (113). This pathway is activated upon a moderate cholesterol load stress and it is proposed 
as a protective mechanism to reduce macrophage cholesterol mass (113). Other genes involved in 
immune regulation are similarly altered in Tspo-/- mice (see Table 2) further validating a role for TSPO 
in the regulation of these processes. Tmem178 is proposed as a negative regulator of macrophage 
activation and Ca2+ signaling at the ER level (114), and is reduced in Tspo-/- mice. Conversely, there 
are increased levels of Zbtb7b, which is associated with T-cell maturation (115) and regulates the 
development of Natural Killer T (NKT) cells (116) and ties in the Tu et al study (110) with the recent 
work by Banati et al (32), who observed an increase in NKT cells present during haematological 
analysis in female Tspo-/- mice. TSPO has previously been reported as having antiretroviral activity 
by inhibiting Env protein expression (117). In support of this study, decreased levels of Trim12a, 
coding for protein within the anti-retroviral TRIM family, and Pydc4, coding for an AIM2-like receptor 
that activates STING-dependent interferon (IFN) production as part of the antiviral response (118), 
were observed in Tspo-/- mice (110). The reduced levels suggest that TSPO is involved in an upstream 
transcriptional signaling cascade that influences the antiviral response.    
Another interesting observation in Tspo-/- mice is a disparity in body weight that occurs only in females, 
with an increase in weight in the knock-out strain (34), which the authors attribute to a hormone-
dependent metabolic pathway. Previously the TSPO ligand, PK 11195, was shown to alter the 
expression of metabolic genes in white adipose tissue (22) and liver (29) of male mice although no 
study has examined the application of ligands in female mice yet to assess possible sexual disparity 
in ligand efficacy. Notably PPARα, regulated by hormones and cAMP, holds a key role in integrating 
the mammalian clock and energy metabolism (119) and notably influences Tspo transcriptional 
regulation (48). Since gender based differences have been observed previously in metabolic patterns 
of circadian rhythms (120) , this may be an explanation for the gender-based differences in body 
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weight seen in Tspo-/- mice. This is particularly interesting as it could reveal a therapeutic potential for 
TSPO ligands in the development of gender-based personalized medicine for human diseases 
relating to metabolic disorders, which are often linked to circadian disruption (121).  
The overarching conclusions that are consistent between all the knock-out studies indicate that due 
to the relative lack of phenotype in Tspo-/- mice, TSPO is likely to be most involved in pathological 
and stress-related conditions. Future follow on studies could therefore focus to assessing 
susceptibility in standard stress models of diseases where TSPO has already been linked to, for 
example, LPS-induced inflammation, ischemia-reperfusion injury, radiation/chemical-induced 
cancers, overfeeding or bacterial/viral infection. Nonetheless, age-related studies should also be 
recommended based on the brain-imaging evidences lately produced (96). 
 
TSPO and its molecular partnership with VDAC1 
TSPO is included in a complex with the 32kDa voltage-dependent anion channel (VDAC) (17), of 
which there are three different isoforms. The relative ratio of these proteins is tissue and condition 
dependent (122). Early studies indicate that 4-6 molecules of TSPO associate with one molecule of 
VDAC to form a single mitochondrial pore (5, 123) but the precise biochemical properties governing 
the interaction remain unclear and require further investigation, which may be facilitated with the 
recent high-resolution characterization of its 3D structure (80).  
There is a growing body of work that supports a functional interplay between TSPO and VDAC 
particularly in dictating the efficiency of mitochondrial metabolism and quality control.  
The long standing role of TSPO in steroidogenesis appears to be linked to its interactions with VDAC 
(124, 125), and relative levels of each protein have comparative expression profiles in steroidogenic 
tissues (126). STAR, TSPO and VDAC all contain binding motifs for 14-3-3ε, a newly identified 
negative regulator of cAMP-mediated induction of steroidogenesis (124, 127). VDAC is a primary 
target of 14-3-3ε, with which forms a protein-protein scaffold that influences downstream TSPO 
interactions leading to reduced cholesterol import into mitochondria (124). In fish testis, tspo and vdac 
mRNA levels are both correlated with reproductive stage and gonadosomatic index (GSI) while in 
females, gonadal tspo and vdac expression are negatively correlated with GSI and levels of plasma 
testosterone and 17β-estradiol (126). 
As mentioned above, TSPO has a regulatory metabolic role. For example the ligands, FGIN-1-27 and 
PPIX are both shown to reduce glycolytic activity and cellular ATP levels (128, 129) while PK 11195 
increases ATP levels (130).  TSPO overexpression is associated with reduced Ca2+-dependent 
activation of mitochondrial respiration (41), which has been linked to VDAC activity while the effect of 
PK 11195 on quinolinic acid-induced glucose metabolic disturbance is reported to involve VDAC 
(131).   
TSPO is strongly associated with inflammation, and studies have demonstrated the importance of the 
TSPO-VDAC interplay in this response too. In vascular endothelial cells, TNFα and other 
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inflammatory cytokines induce mitochondrial ROS production and expression of vascular cell 
adhesion molecule-1 (VCAM-1) although TSPO overexpression interferes with this sequence of 
events (132). In contrast to the apparent parallel expression profiles in steroidogenic tissues, TSPO 
expression negatively correlates with VDAC1 expression in endothelial cells, an observation that the 
authors attribute to the reduced mitochondrial ROS and lower levels of VCAM-1 in overexpressing 
TSPO conditions (132). 
The mitochondrial TSPO-VDAC complex is further involved downstream of PARK2-mediated activity 
(41, 133). We determined that increased TSPO expression in mouse embryonic fibroblast cells leads 
to a reduction in PARK2-mediated mitochondrial ubiquitination during FCCP-induced mitophagy (41). 
Mechanistically, VDAC1 was required for this TSPO-dependent activity and further attributed to a 
ROS-signaling pathway since mitophagy could be restored in over-expressing TSPO cells in the 
presence of the antioxidant, MnTBAP (Manganese (III) tetrakis (4-benzoic acid)porphyrin chloride) 
(41).  
A further study has confirmed a role for TSPO-VDAC in regulating PARK2 function, showing that 
TSPO-VDAC is involved downstream of the PARK2-mediated immune response in Drosophila since 
PARK2 overexpression failed to rescue lethality caused by septic injury in TSPO-silenced larvae (133) 
.  
This evidence suggests that the interplay between VDAC and TSPO is important in all the major 
functions attributed to TSPO including steroidogenesis, hormone biosynthesis, immune/inflammatory 
regulation and energy metabolism, processes for which mitochondria are critically involved. The 
removal of different VDAC isoforms can yield mice without mitochondrial dysfunction or evident 
phenotype, which is also the case in certain strains of TSPO KO mice (please see section above). 
This may appear particularly confounding, as each of these proteins can comprise up to 5% of total 
outer mitochondrial membrane protein levels in certain tissues. However, some functional redundancy 
has been described between the various VDAC isoforms, which may explain the apparent lack of 
phenotype. Furthermore, in the case of the VDAC1-/- strains, there was considerable variation in 
phenotype, which was notably dependent upon the methodology used to generate the line. VDAC1-/- 
mice obtained from a mixed genetic background (C57BL6/129SvEv) were born at a lower than 
expected mendelian ratio whilst VDAC1-/- mice, bred onto the C57B16 background, showed near 
complete lethality (134). 
 
 
TSPO in cellular and tissues pathology 
Cancer 
TSPO is overexpressed in a variety of cancers including those affecting the brain (135). TSPO 
expression is elevated in human prostatic intraepithelial neoplasia, primary prostate cancer and 
metastases when evaluated against normal prostate tissue and benign prostatic hyperplasia (136). A 
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positive correlation with disease progression was observed too and immunohistochemical studies in 
oral cancer have yielded similar results. Interestingly, the five-year survival probability dropped from 
65% in patients with TSPO negative tumors to just 7% in patients with high tumoral TSPO content 
(137). Results, from colorectal carcinomas in human patients, indicated that TSPO was 
overexpressed in 67% of tumors in comparison to corresponding normal mucosa in which expression 
was found to be significantly higher. And in this study, TSPO did not differ for expression between 
intermediate versus high-grade tumors or in lymph node-positive versus negative patients (138). 
Overexpression of TSPO has also been observed in breast cancer cell lines (139) and in clinical 
studies (140). In the former, estrogen receptor-negative breast cancer cell lines had significantly 
higher TSPO expression compared to ER-positive lines and the levels of TSPO were positively 
correlated with the proliferation marker, Ki-67 (139). This observation was mirrored in the clinical study 
in which TSPO expression was significantly increased in tumoral versus normal breast cells and 
TSPO was again correlated with Ki-67 levels. TSPO was anyway never associated with reduced 
prognosis in the whole patient sample, but in lymph-node negative group of patients, elevated TSPO 
was linked to a shorter disease-free survival period, indicating that TSPO could be used to identify a 
higher risk population in this category (140). TSPO is reported overexpressed in oesophageal cancer 
cells compared to normal oesophageal epithelium (141), as well as in human endometrial carcinoma, 
where significantly more mitochondrial TSPO was observed in contrast to normal endometrium (142). 
The link between TSPO and cancer is therefore consolidated even though the underlying pathogenic 
mechanism driving a primary oncogenic profile is still lacking. 
Inflammatory Brain conditions  
High levels of TSPO are recurrently associated with glial cell activation and inflammation (143, 144). 
Chronic inflammation is an early feature of many neurological conditions and other age-related 
conditions including atherosclerosis [reviewed in (145)]. Uptake of TSPO ligands in the brain is 
generally low in normal healthy adults, but overall uptake is increased with age (146). An increase in 
TSPO expression has been observed during the onset of disease in amytrophic lateral sclerosis (ALS) 
patients (147). Similarly, brains of subjects with mild cognitive impairment (MCI), who are at an 
increased risk of developing Alzheimer’s disease (AD), or subjects with mild and early forms of AD, 
exhibit higher ligand binding compared to age-matched controls (148, 149) although other studies 
contradict this observation (150). Widespread glial activation is likewise associated with the 
pathological process that occurs in Parkinson’s disease (PD) and TSPO ligands have shown 
increased binding profiles in rat models mimicking the early stages the disease (151). Clinical studies 
show that compared to controls, PD patients have increased levels of TSPO ligand binding in the 
regions of the brain (152), although the degree of binding did not alter over a two-year period and was 
not associated with clinical severity demonstrating that TSPO overexpression and inflammation are 
likely early diagnostic factors (153). In stroke patients, TSPO expression and glial activation is 
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increased in the peri-infarct zone for several weeks following insult (154) while bio-imaging has 
revealed elevated TSPO expression in inflamed atherosclerotic plaques of the vasculature (155, 156). 
The precise molecular mechanisms characterizing a functional role for TSPO in these diseases are 
unclear leaving a general understanding that the upregulation of TSPO is an adaptive consequence 
rather than a causative factor on which the mitochondrial dependent rewiring of cell signaling and 
metabolism of the cells, is affected. It is anyway known that factors playing part in the regulation of 
TSPO expression such as ROS, Interleukin-1 (IL-1) and TNF , are clearly involved in this process 
suggesting that a molecular pro-inflammatory role is plausible (18, 157). 
TSPO is also implicated in peripheral inflammatory diseases for example the Inflammatory Bowel 
Disease (IBD). In this it has been demonstrated an increase in TSPO expression in the colon likewise 
in human intestinal biopsies from IBD patients (18). TSPO ligands have been indeed developed or 
adapted along the years to illustrate areas of inflammation through in vivo imaging analysis, making 
this one of the most active fields for biomedical applications targeting the protein. Interestingly, almost 
unexplored is whether these same tools may be effective as therapeutic means against the diseases 
in which they are adopted.  In this regard, some preliminary material seems to support this notion (21, 
24, 158) but more is to be done. 
 
The pharmacology of a natural mitochondrial target  
The consolidated profile as a multi-drugs binding protein has made TSPO a topic of natural interest 
for pharmacologists. Numerous are indeed the publications reporting the use of TSPO targeting 
chemicals to dissect and/or correct biological processes associated with the protein. The archetype 
synthetic TSPO ligands, prevalently used are the 4’-chloro-derivative of diazepam, Ro 5-4864, and 
the isoquinoline carboxamide, PK11195 which respectively bind TSPO with nanomolar affinity even 
though this is greater for PK11195 (KD <20nM) (159). Several endogenous ligands for the protein 
have been also identified among the porphyrins (cholesterol, hemin, protoporphyrin IX, 
mesoporphyrin IX, deuteroporphyrin IX) (160, 161). 
In spite of the extensive use, the most recent evidences suggest that these may not be so reliable 
since Ro 5-4864 varies its efficacy across species whilst PK11195, exerts cellular effects independent 
of TSPO (162-165) soon as it is over-dosed (µM rather than nM). 
This has consequently stimulated the search for alternative compounds based on different chemical 
structures. Another class of compounds generated and still binding TSPO with nM affinity was 
identified in the 2 aryl-3-indoleacetamides (FGIN-1) (166), which retains good cross-species efficacy. 
Furthermore this drug does hold anxiolytic-like effects (167) likewise the XBD173 (AC-5216; 
Emapunil). The mechanisms by which these two chemicals operate are univocal by inducing a boost 
of the production of neurosteroids. Once they are bound to TSPO they would in turn potentiate the 
GABAA receptor-based neurotransmission leading to a beneficial effect linked with the regulatory 
cascade depending on this receptor. 
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However, a series of highly specific synthetic ligands for TSPO have been successfully developed in 
the form of radiotracers for PET bio-imaging of inflammation, for example the 7-chloro-N,N,5-
trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (SSR180575) (168) 
and 2-(5, 7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide 
(VUIIS1008) (169) and the 12a ([(18)F]GE-180).  Thus, the exploitation of TSPO upregulation for the 
in vivo diagnostic imaging of patients is probably the primary and mostly corroborated clinical value 
for TSPO and holds the potential to grow and extend across multiple fields by refinement in the 
chemistry of TSPO-binding ligands in order to overcome imaging complications. In spite of this the 
pharmacological regulation of TSPO does remain debated.  
Very recently Selvaraj and Stocco have, very timely and elegantly, stimulated attention towards the 
word ‘ligand’ as loosely used in the TSPO literature in reference to all substances that bind TSPO at 
various distinct sites (170). This is quite appropriate, as findings on ligand-binding response have 
proved inconsistent along the years, ranging from steroid hormone production to cell proliferation, 
signaling and apoptosis. The word ligand thus describes a small-molecular substance that binds to a 
target biomolecule (or complex) without the need to elicit or modulate a specific biological response 
as required instead by an agonistic or antagonistic whcich directly associated with the function of the 
target. In the case of TSPO such function is -for now- represented solely by the translocation of 
cholesterol and consequent synthesis of steroids.  
However, gene-edited animal models for TSPO do not reassemble, challenged with TSPO-binding 
chemicals, the pharmacological effects recorded in vitro experiments, implying these chemicals may 
have alternative biochemical/pharmacological relevance beyond TSPO or the TSPO dependent 
translocation of cholesterol may not represent per se the perfect assay to sample their activity. 
Although basal steroids could be still formed without TSPO being expressed a regulatory role for the 
protein cannot be excluded and thus TSPO ligands, which do mediate a robust effect on steroids as 
well as neurosteroids formation, may also be affected. 
The manufacture of steroids might indeed entail concurrent limiting steps depending on alternative 
molecular elements and therefore likely to be too elaborated to allow fast discrimination of TSPO 
pharmacology. The effort should be therefore to outline alternative fast-response assays, which could 
insight, not only the binding capacity but also the agnostic/antagonistic profiles of the compounds.  
In this the recent advancements in comprehending the structure and the functional role of TSPO in 
respect of cell signaling mitochondrial cell biology may represent the solution. Even without a direct 
etiological link, this quest for TSPO-binding therapies has been extensive in recent years and applied 
to various diseases prompted by the pressing need for drug discovery pipelines, being the 
upregulation of TSPO constant in pathological lesions.  
Thus, TSPO ligands have still proven efficacious in ameliorating disease pathology in numerous 
preclinical models and most remarkably in models bearing phenotypes in the central nervous system 
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(24, 171-173). Recently, Ro5-4864 was shown to amend Alzheimer’s disease associated phenotypes 
in vivo (25) by mediating positive effects in steroid hormones production (109) (Table 3).  
Human clinical trials have been performed for Emapunil to treat anxiety disorders with promising 
outcomes reported in an induced model of panic disorder (31). However, the high TSPO binding 
variability across human subjects -recently observed- does render unlikely a drug development via 
this mechanism of targeting (operating by inducing a boost of the production of neurosteroids as 
recorded following challenge with TSPO ligands) which remains, anyhow the most promising one 
(174). On the other hand, the early assessment of mutations in TSPO (e.g. A147T SNP), via advanced 
imaging protocols, could lead to personalized therapies and consequent tangible benefit for patients. 
What is known since long time is that TSPO-binding drugs can cause death of cancer cells and 
therefore considered potential anticancer therapies. This was prevalently associated with the putative 
role of TSPO in activating the Mitochondrial Permeability Transition Pore (MPTP) that was also 
hypothesized to be involved in the protection mediated by the TSPO ligands as heart protectors and 
tools to reduce infarct size after ischemia-reperfusion (175, 176). The recent advancements in the 
clarification of the MPTP molecular entity rule TSPO in its formation and regulation and therefore in 
the consequent protein-associated pharmacological mechanisms thus calling for these to be clarified 
if therapeutic uses are to be exploited. 
This further highlights how structure and conformational adaptation of the protein are essential to 
better dissect the pharmacology of this pathway and in this way ease the comprehension and 
validation of current and future chemicals.  
 
Concluding remarks 
 
The aspects of TSPO above discussed report of a multifaceted mitochondrial pathway characterized 
by interdisciplinary interest. The evidences gathered along the years have enriched the landscape of 
TSPO science favoring its current exploitation by diagnostic and therapeutic protocols. 
Being brought up to general attention, as an off-target binding site of the benzodiazepines TSPO is 
now a corroborated regulatory element in the mitochondrial and cellular pharmacology of lipids. 
In the attempt to interpret the series of information homogenously it seems that the accumulation of 
TSPO, reconciled during inflammation and therefore targeted by advanced protocols of in vivo 
imaging, prevents the removal of mitochondria by the autophagy-operated quality control 
mechanisms leaving the organelles to be primed by the cells for steroids synthesis and undermining 
other core functions that are indeed compromised by the accumulation of TSPO.  
The concerted cooperation among disciplines, a structured cooperation by experts and the 
advancements in the technology and experimental protocols will continue to improve and modernize 
TSPO science incrementing its significance in mammalian pathophysiology to obtain an informed 
understanding of this regulator and target of the mitochondrial function. 
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Legends to Figures 
 
Figure 1: TSPO transcriptional regulation- crosstalk between hormone and REDOX sensitive signal 
transduction pathways 
Hormonal stimuli that bind to G-protein coupled receptors (GPCR) in the plasma membrane results in cAMP 
synthesis from ATP via adenylate cyclases. cAMP is a signaling molecule that triggers the release of ACBD3 
from the Golgi, which translocates to mitochondria, where it recruits PKA through its interaction with TSPO. 
PKA has been demonstrated to phosphorylate TSPO and VDAC and its kinase activity is dependent upon local 
concentrations of cAMP. cAMP also activates PPARα, which interferes with Tspo transcription factors including 
AP-1. TSPO is also sensitive to changes in REDOX status. Cytoplasmic or mitochondrial sources of ROS may 
activate the PKCε-Raf1-MEK1/2-ERK1/2 signaling cascade, which promotes Tspo transcription via the activity 
of c-Jun and STAT-3 transcription factors. An increase in TSPO may potentiate this response by maintaining 
an oxidative environment. ROS have also been demonstrated as promoting the formation of TSPO multimers. 
VDAC – voltage dependent anion channel; TSPO – translocator protein; ACBD3 – Acyl-coenzyme A binding 
domain containing 3; PKA – cAMP dependent protein kinase A; cAMP - cyclic adenosine monophosphate; ROS 
– reactive oxygen species; PPARα - peroxisome proliferator-activated receptor alpha; STAT3 – signal 
transducer and activator of transcription 3; AP-1 – activator protein 1 
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Figure 2: TSPO domain architecture and cross-species sequence alignment  
Sequence alignment of TSPO using ClustalX software, showing conserved regions including the cholesterol-
binding domain (CRAC sequence) in rhodobacter sphaeroides TspO, Homo sapiens, mus musculus and canis 
lupus familiaris. Transmembrane (TM) domains are denoted by black lines (TM1: 6-26 a.a; TM2: 47-67 a.a; 
TM3: 80-100 a.a; TM4: 106-126 a.a; TM5: 135-155 a.a.). Loops 1 (6-26) and 3 are cytosolic; loops 2 and 4 are 
facing the mitochondrial intermembrane space. The longer cytosolic loop 1 is implicated in dimerization, 
possible VDAC interaction, and the binding of ligands. b) The default colour scheme used for sequence 
alignments generated in ClustalX, the graphical interface for the ClustalW multiple sequence alignment 
programs. Residues in the alignment are assigned a colour according to the amino acid profile. The table shown 
gives the criteria as clauses +X%, xx, y; where X is the minimum percentage presence of any of the xx or y 
residues accompanied by a functional profile. White regions are unconserved. 
 Global C57BL/6-
Tspotm1GuMu(GuwiyangWurra) 
Global (Tu et al) Nr5a1-Cre Driven Tspo 
Conditional Knockout 
Mitochondria 
phenotype 
reduced microglial 
mitochondrial metabolic 
activity 
Mitochondrial volume in 
primary fibroblasts 
unchanged; Mitochondrial 
morphology unchanged in 
testis and ovary 
 
Body weight No differences observed Increased body weight in 
female mice (~1g, 1-5 weeks 
of age) 
 
Lipid metabolism  No effect on lipid deposits in 
adrenals 
Depletion of lipid storage in 
testis; Increased 
accumulation of lipids in 
adrenals 
Hormone-induced 
steroidogenesis 
 hCG-induced plasma 
testosterone unchanged 
Increased levels of plasma 
estradiol 
Impaired ACTH stimulation of 
corticosterone production 
hCG-induced plasma 
testosterone unchanged 
Increased epinephrine 
production 
Steroidogenesis No change in basal 
steroidogenesis 
No change in basal 
steroidogenesis 
No change in basal 
steroidogenesis 
 
Immune response Microglial activation 
following neuronal injury 
normal; 
Increased levels of NKT 
cells in female mice 
  
!
TSPO Function Gene Tissue  Protein product function Expression 
Immune Response Tmem178 Adrenal Negative regulator of macrophage 
activation 109 
!106!
 
Zbtb7b Adrenal T-cell maturation 110, 111 "106 
Trim12a Adrenal Anti-viral response 
 
!106!
 
Pydc4 Adrenal Anti-viral response 113 !106!
Hormone 
Regulation 
Cyp21a2 Adrenal P450 enzyme required for adrenal 
steroidogenesis 117 
"106 
Abca2 Adrenal Regulates cholesterol efflux to 
ApoE3 118 
"106 
Scarb1 Adrenal Mediates uptake of HDL-derived 
cholesterol and cholesteryl ester 
119 
"107 
Lhcgr Testes Hormone receptor, required for 
reproduction  
"107 !
Table 1: Phenotypic characterization of global and conditional Tspo-/- mice 
Table 2: Compensatory gene expression in Tspo-/- mice: focus on the immune  
response and hormone regulation 
Ligand Chemical Class 
 
Disease-relevant study Outcome Ref 
ZBD-2 Phenylpurine 
acetamide 
Mouse: Middle cerebral artery 
occlusion 
Neuroprotection 168 
Mouse: Hindpaw injection of 
Freund's adjuvant (CFA) 
Altered excitatory and inhibitory 
transmission in the basolateral 
amygdala (BLA), reduced anxiolytic 
effects 
174 
Midazolam 
 
Benzodiazepine Rat: Single prolonged stress 
model 
Reversed PTSD-associated freezing 
and anxiety-like behaviour via 
neurosteroidogenesis 
175 
YL-IPA08 Pyridazinoindole 
acetamide 
Mouse: Inescapable electric 
foot shock induced model of 
PTSD 
Reduced anxiety and fear, mediated 
by allopregnanolone synthesis; 
antagonized by PK 11195 
176 
Mouse: Novelty suppressed 
feeding test, Vogel drinking 
conflict test, elevated plus-
maze test, forced swimming 
test; tail suspension test 
Anxiolytic and antidepressant effects 177 
PK 11195 Isoquinoline 
carboxamide 
Rat: Model of cortical contusion 
with hyperbaric oxygen therapy 
Reversed protective effects of 
hyperbaric hyperoxia in brain injury 
178 
Etifoxine Benzoxazine Mouse: Experimental 
autoimmune encephalomyelitits 
(EAE) model 
Reduced imflammatory pathology in 
spinal cord, promoted oligodendoglial 
regeneration; promoted recovery 
when administered before and after 
development of symptoms 
24 
Ro-5-4864 Benzodiazepine Rat: 30 min coronary occlusion/ 
15 min reperfusion  
Reduced infarct size and improved 
mitochondrial function post injury, 
reduced oxidative stress and oxysterol 
formation by lowering cholesterol 
accumulation 
179 
Mouse: Lesion to facial nerve in 
adults 
Treated mice showed improved 
recovery of whisker function and 
whisker pad reinnervation 
180 
Rat: Single injection of 
streptozotocin in sciatic nerve 
to simulate diabetes 
Stimulate levels of pregnenolone, 
progesterone and testosterone in 
sciatic nerves, restored skin 
innervation density, improved Na+,K+-
ATPase activit. 
181 
MPIGA Phenylindolylgly 
oxylamide 
Rat: Elevated maze test Anxiolytic effects 182 
FGIN-1-27 Arylindol 
acetamide 
Mouse: Subcutaneous 
xenograft of HT29 cells in right 
thigh  
40 % reduction in the growth rate of 
grafted tumors 
183 
Rat: L5 spinal nerve ligation  Reduced mechanical allodynia and 
thermal hyperalgesia; same effects 
observed with Ro5-4864 
184 
SSR 
180575 
Pyridazinoindole 
acetamide 
Mouse: MRL/lpr model TSPO ligands reduced pulmonary 
inflammation and alveolitis onset; 
similar effects seen with PK 11195 
and Ro5-4864 
185 
Mouse: MRL/lpr model Delayed onset of arthritis symptoms 28 
Emapunil Phenylpurine 
acetamide 
Rat: Social exploration test; rat 
elevated plus maze test 
Anxiolytic activity 31 
Mouse: Vogel-type conflict test; 
light/dark box, social interaction 
tests 
Anti-anxiety effects 31 
Rat: Forced swimming test Anti-anxiety effects 186 !
Table 3: in vivo assessment of TSPO ligands in animal models of disease 
